Latest Breaking News On - இனப்பெருக்கம் விசாரணை - Page 1 : comparemela.com

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABOS) - The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABOS) - The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Colitis organizationAlector incAltimmune incAerovate therapeutics incMorphic holding incAngion biomedica corpCvrx incBiopharma incAcumen pharmaceuticals incSociety for reproductive investigationEuropean academy of allergyChemocentryx incWall streetAcumen pharmaceuticalsAerovate therapeuticsAnnual congress

ObsEva to Present Ebopiprant (OBE022) Data at the Society

ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F 2α receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF 2α is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.

United statesShauna dillonJoyce allaireExchange commissionMerck kgaIndustry development in preterm labor treatmentSociety for reproductive investigationMerck kgaaSwiss exchangeReproductive investigationAnnual meetingBoston julyProof of concept trialSpontaneous preterm laborElizabeth garnerChief medical officer

ObsEva SA: ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

ObsEva SA: ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting ePoster , 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF 2 a) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68 th Annual Meeting, being held virtually and in Boston July 6 -9, 2021. Presentation details are as follows: Abstract ID: W-063 Session Session Time: 4:00-5:30 p.m. ET

Shauna dillonJoyce allaireExchange commissionMerck kgaIndustry development in preterm labor treatmentSociety for reproductive investigationMerck kgaaSwiss exchangeReproductive investigationAnnual meetingBoston julyProof of concept trialSpontaneous preterm laborElizabeth garnerChief medical officerPharmaceutical industry development

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesShauna dillonJoyce allaireExchange commissionMerck kgaIndustry development in preterm labor treatmentSociety for reproductive investigationMerck kgaaSwiss exchangeReproductive investigationAnnual meetingBoston julyProof of concept trialSpontaneous preterm laborElizabeth garnerChief medical officer

Shady Grove Fertility (SGF) Welcomes Reproductive Endocrinologist, Emily Barnard, D O , to the Washington, D C and Towson Physician Teams

Skip to main content Currently Reading Shady Grove Fertility (SGF) Welcomes Reproductive Endocrinologist, Emily Barnard, D.O., to the Washington, D.C. and Towson Physician Teams PRWeb FacebookTwitterEmail WASHINGTON (PRWEB) March 01, 2021 Shady Grove Fertility (SGF) is proud to announce that reproductive endocrinologist, Emily Barnard, D.O., has joined the practice and will begin seeing patients at SGF’s Washington, D.C. - K Street and Towson offices in April 2021. Dr. Barnard will provide a full range of state-of-the-art, in-house diagnostic and treatment options for female and male infertility, elective egg freezing, LGBTQ family building, and fertility preservation prior to cancer treatment.

United statesEric widraEmily barnardAmerican society for reproductive medicineNational infertility associationKansas city university of medicineAmerican congressSociety for reproductive endocrinologySociety for reproductive investigationSociety of gynecologic surgeonsMayo international health program scholarshipGrove fertilityWelcomes reproductive endocrinologistTowson physicianKansas city universityInternational health program scholarship